ipilimumab + Nivolumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Apr 1, 2016 → Jul 22, 2021
NCT ID
NCT02626962About ipilimumab + Nivolumab
ipilimumab + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02626962. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05200988 | Phase 2 | Active |
| NCT04933903 | Phase 2 | Recruiting |
| NCT04969887 | Phase 2 | Active |
| NCT04463368 | Phase 1 | Completed |
| NCT04717154 | Phase 2 | Completed |
| NCT04124601 | Phase 2 | Completed |
| NCT04118166 | Phase 2 | Completed |
| NCT03340129 | Phase 2 | Recruiting |
| NCT03682276 | Phase 1/2 | UNKNOWN |
| NCT03305445 | Phase 1 | Completed |
| NCT03425331 | Phase 2 | Terminated |
| NCT03387761 | Phase 1 | Completed |
| NCT03333616 | Phase 2 | Active |
| NCT03203473 | Phase 2 | Active |
| NCT03168464 | Phase 1/2 | Terminated |
| NCT02892734 | Phase 2 | Terminated |
| NCT02923934 | Phase 2 | Completed |
| NCT03146650 | Phase 2 | UNKNOWN |
| NCT03122522 | Phase 2 | Active |
| NCT03043599 | Phase 1/2 | Completed |
Competing Products
20 competing products in Uveal Melanoma